Portfolio Companies

Imel BioTherapeutics

04/20/2020
IMEL Biotherapeutics is developing a cell-based therapy which represents a new paradigm for the treatment of patients with mitochondrial disorders. Using its proprietary Mitochondrial DNA Replaced Cell technology, IMEL will enable to treat multiple patients with mitochondrial genetic and age-related disorders.